SCHEMBL1822010

SCHEMBL1822010

Oc1ccc(/C=C/c2ccc(O)cc2O)c(O)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 3/20 0.75
TTR P02766 2/20 0.75
SYNJ2 O15056 1/20 0.75
CYP1A1 P04798 1/20 0.75
BCHE P06276 1/20 0.75
MMP2 P08253 1/20 0.75
ALOX5 P09917 1/20 0.75
PTPN1 P18031 1/20 0.75
PTGS1 P23219 1/20 0.75
CYP1B1 Q16678 1/20 0.75
PTPN22 Q9Y2R2 1/20 0.75
CHRNA7 P36544 7/20 0.59
BACE1 P56817 1/20 0.53
MEN1 O00255 1/20 0.48
ALPL P05186 1/20 0.48
POLB P06746 1/20 0.48
ALPI P09923 1/20 0.48
ALPG P10696 1/20 0.48
KMT2A Q03164 1/20 0.48
EIF4H Q15056 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1822012 1.00 TYR (0.75) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL31006919 0.91 TYR (0.64) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL2166274 0.89 TYR (0.62) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL1824476 0.89 TTR (0.68) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL1824473 0.89 TTR (0.68) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL1822477 0.89 PTGS1 (0.74) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL12091582 0.89 PTGS1 (0.74) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL1822480 0.89 PTGS1 (0.74) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL2166277 0.89 TYR (0.62) TYRTTRSYNJ2CYP1A1BCHE
SCHEMBL31006923 0.89 TYR (0.62) TYRTTRSYNJ2CYP1A1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436538-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION Merryvital AG (CH) 2024-10-02 EP claimed
EP-3654929-B1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE OREAL (FR) 2024-05-29 EP claimed
WO-2023094852-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION MERRYVITAL AG (CH) 2023-06-01 WO claimed
EP-3654929-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2020-05-27 EP claimed
WO-2019016153-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2019-01-24 WO claimed
EP-2315583-B1 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE YVERY (FR) 2018-05-09 EP claimed
JP-2011528336-A 2011-11-17 JP claimed
US-20110184072-A1 FORMULATION INTENDED TO IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE PECHERE LAURENT 2011-07-28 US claimed
EP-2315583-A2 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE Yvery (FR) 2011-05-04 EP claimed
WO-2010007252-A2 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE YVERY (FR) 2010-01-21 WO claimed
US-20020183400-A1 Composition for topical application comprising at least one hydroxystilbene and at least one polyol to solubilize the hydroxystilbene L'OREAL (FR) 2002-12-05 US claimed
EP-1234571-A1 Topical composition containing a hydroxystilbene and a polyol L'OREAL (FR) 2002-08-28 EP claimed
US-6440433-B1 TREATING MENOPAUSAL SKIN DISORDERS; APPLYING TOPICAL MIXTURE TO IMPART AGING RESISTANCE; ACTIVATING SKIN FIBROBLAST PROLIFERATION SOCIETE L'OREAL S.A. (FR) 2002-08-27 US claimed
EP-1068864-A1 Use of at least a hydroxystilbene as a glycation inhibitor L'OREAL (FR) 2001-01-17 EP claimed
EP-1064931-A1 Cosmetic composition containing at least an hydroxystilbene and ascorbic acid L'OREAL (FR) 2001-01-03 EP claimed
US-6147121-A TOPICALLY APPLYING HYDROXYSTILBENE DERIVATIVE TO TREAT SKIN AGING AND WRINKLES SOCIETE L'OREAL S.A. (FR) 2000-11-14 US claimed
US-6124364-A Desquamation/epidermal renewal of the skin and/or combating skin aging SOCIETE L'OREAL S.A. (FR) 2000-09-26 US claimed
EP-0953346-A1 Use of at least a hydroxystilbebe in a skin fortifying composition L'OREAL (FR) 1999-11-03 EP claimed
EP-0953344-A1 Use of at least one hydroxystilbene in a composition to stimulate desquamation of the skin and compositions containing it L'OREAL (FR) 1999-11-03 EP claimed
EP-0953345-A1 Use of at least a hydroxystilbene as an agent for decreasing micro-organism adhesion L'OREAL (FR) 1999-11-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184072-A1 FORMULATION INTENDED TO IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE FABP2, SI, SLC10A2 TYR 4500/4885TTR 523/4885SYNJ2 2422/4885
US-20020183400-A1 Composition for topical application comprising at least one hydroxystilbene and at least one polyol to solubilize the hydroxystilbene CYP8B1, HSD17B1, HSD11B1 TYR 2084/4885TTR 3195/4885SYNJ2 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.